Aspira Women’s Health Inc. (NASDAQ:AWH) Sees Significant Growth in Short Interest

Aspira Women’s Health Inc. (NASDAQ:AWH) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 169,400 shares, a growth of 26.2% from the March 31st total of 134,200 shares. Currently, 2.5% of the company’s stock are sold short. Based on an average trading volume of 27,900 shares, the days-to-cover ratio is presently 6.1 days.

Hedge Funds Weigh In On Aspira Women’s Health

Several large investors have recently made changes to their positions in AWH. B. Riley Wealth Advisors Inc. increased its position in shares of Aspira Women’s Health by 43.1% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 179,371 shares of the company’s stock valued at $732,000 after buying an additional 53,997 shares in the last quarter. Perkins Capital Management Inc. acquired a new position in Aspira Women’s Health during the third quarter worth $268,000. Northeast Financial Consultants Inc purchased a new position in Aspira Women’s Health during the third quarter valued at $126,000. Finally, Quantum Private Wealth LLC grew its position in shares of Aspira Women’s Health by 76.8% in the fourth quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock valued at $205,000 after purchasing an additional 21,788 shares during the period. 12.19% of the stock is currently owned by institutional investors and hedge funds.

Aspira Women’s Health Price Performance

NASDAQ:AWH traded down $0.11 during midday trading on Tuesday, hitting $3.22. The company’s stock had a trading volume of 9,565 shares, compared to its average volume of 29,550. The firm’s 50 day moving average is $3.55 and its 200-day moving average is $3.97. The firm has a market cap of $39.73 million, a P/E ratio of -0.27 and a beta of 1.61. Aspira Women’s Health has a fifty-two week low of $2.31 and a fifty-two week high of $6.75.

Aspira Women’s Health (NASDAQ:AWH) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.09. The company had revenue of $2.13 million for the quarter, compared to the consensus estimate of $2.70 million. Aspira Women’s Health had a negative return on equity of 1,099.32% and a negative net margin of 176.74%. As a group, analysts forecast that Aspira Women’s Health will post -1.24 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on AWH. Cantor Fitzgerald reiterated a “neutral” rating and set a $3.30 price objective on shares of Aspira Women’s Health in a report on Wednesday, April 10th. StockNews.com assumed coverage on Aspira Women’s Health in a research report on Saturday. They issued a “hold” rating on the stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.